Heparin-induced thrombocytopenia: a tremendous opportunity for randomization

Research output: Contribution to journalArticle

Abstract

Heparin-induced thrombocytopenia and thrombosis (HITT) is both life-threatening with a complex immune-mediated process and clinically challenging to diagnose and treat. What further complicates matters is that thrombocytopenia is a frequently encountered laboratory value but rarely results in clinical signs of HITT. Decades into its initial description, we have anticoagulants with a small therapeutic index and associated high cost. The diagnosis is sometimes equivocal given our current laboratory diagnostics, and can take days to confirm. Furthermore, prior studies that resulted in the approval of anticoagulants for the treatment of heparin-induced thrombocytopenia have been imperfectly designed. Further evaluations of patients with HITT could more adequately define these difficult issues.

Original languageEnglish (US)
JournalBlood Coagulation and Fibrinolysis
DOIs
StateAccepted/In press - Oct 25 2016

Fingerprint

Random Allocation
Thrombocytopenia
Heparin
Thrombosis
Anticoagulants
Antigen-Antibody Complex
Costs and Cost Analysis
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

@article{d06d721bc27f471f917a5046cd84549e,
title = "Heparin-induced thrombocytopenia: a tremendous opportunity for randomization",
abstract = "Heparin-induced thrombocytopenia and thrombosis (HITT) is both life-threatening with a complex immune-mediated process and clinically challenging to diagnose and treat. What further complicates matters is that thrombocytopenia is a frequently encountered laboratory value but rarely results in clinical signs of HITT. Decades into its initial description, we have anticoagulants with a small therapeutic index and associated high cost. The diagnosis is sometimes equivocal given our current laboratory diagnostics, and can take days to confirm. Furthermore, prior studies that resulted in the approval of anticoagulants for the treatment of heparin-induced thrombocytopenia have been imperfectly designed. Further evaluations of patients with HITT could more adequately define these difficult issues.",
author = "Austin Lammers and Thomas Deloughery and Vinay Prasad",
year = "2016",
month = "10",
day = "25",
doi = "10.1097/MBC.0000000000000606",
language = "English (US)",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Heparin-induced thrombocytopenia

T2 - a tremendous opportunity for randomization

AU - Lammers, Austin

AU - Deloughery, Thomas

AU - Prasad, Vinay

PY - 2016/10/25

Y1 - 2016/10/25

N2 - Heparin-induced thrombocytopenia and thrombosis (HITT) is both life-threatening with a complex immune-mediated process and clinically challenging to diagnose and treat. What further complicates matters is that thrombocytopenia is a frequently encountered laboratory value but rarely results in clinical signs of HITT. Decades into its initial description, we have anticoagulants with a small therapeutic index and associated high cost. The diagnosis is sometimes equivocal given our current laboratory diagnostics, and can take days to confirm. Furthermore, prior studies that resulted in the approval of anticoagulants for the treatment of heparin-induced thrombocytopenia have been imperfectly designed. Further evaluations of patients with HITT could more adequately define these difficult issues.

AB - Heparin-induced thrombocytopenia and thrombosis (HITT) is both life-threatening with a complex immune-mediated process and clinically challenging to diagnose and treat. What further complicates matters is that thrombocytopenia is a frequently encountered laboratory value but rarely results in clinical signs of HITT. Decades into its initial description, we have anticoagulants with a small therapeutic index and associated high cost. The diagnosis is sometimes equivocal given our current laboratory diagnostics, and can take days to confirm. Furthermore, prior studies that resulted in the approval of anticoagulants for the treatment of heparin-induced thrombocytopenia have been imperfectly designed. Further evaluations of patients with HITT could more adequately define these difficult issues.

UR - http://www.scopus.com/inward/record.url?scp=84992740843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992740843&partnerID=8YFLogxK

U2 - 10.1097/MBC.0000000000000606

DO - 10.1097/MBC.0000000000000606

M3 - Article

C2 - 27787285

AN - SCOPUS:84992740843

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

ER -